Fiduciary Trust Co. continued to hold its stake in shares of MyoKardia, Inc. (NASDAQ:MYOK) during the first quarter, Holdings Channel reports. The fund owned 28,554 shares of the biotechnology company’s stock at the end of the first quarter. Fiduciary Trust Co.’s holdings in MyoKardia were worth $375,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Bessemer Group Inc. acquired a new stake in MyoKardia during the fourth quarter valued at $114,000. Highbridge Capital Management LLC acquired a new stake in MyoKardia during the first quarter valued at $136,000. Aberdeen Asset Management PLC UK acquired a new stake in MyoKardia during the fourth quarter valued at $144,000. A.R.T. Advisors LLC acquired a new stake in MyoKardia during the fourth quarter valued at $148,000. Finally, Daiwa SB Investments Ltd. acquired a new stake in MyoKardia during the first quarter valued at $170,000. 47.74% of the stock is owned by hedge funds and other institutional investors.
MyoKardia, Inc. (MYOK) traded down 3.15% during midday trading on Tuesday, hitting $13.85. The stock had a trading volume of 108,342 shares. The firm’s market capitalization is $435.65 million. MyoKardia, Inc. has a 1-year low of $10.55 and a 1-year high of $22.83. The firm has a 50-day moving average price of $13.48 and a 200-day moving average price of $13.09.
MyoKardia (NASDAQ:MYOK) last released its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by $0.01. The firm had revenue of $5.60 million during the quarter, compared to the consensus estimate of $7 million. MyoKardia had a negative net margin of 39.44% and a negative return on equity of 15.27%. The business’s revenue was up 55.6% on a year-over-year basis. On average, equities research analysts anticipate that MyoKardia, Inc. will post ($1.54) earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Fiduciary Trust Co. Continues to Hold Stake in MyoKardia, Inc. (MYOK)” was first posted by sleekmoney and is owned by of sleekmoney. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://sleekmoney.com/fiduciary-trust-co-continues-to-hold-stake-in-myokardia-inc-myok/1925838.html.
MYOK has been the subject of several research reports. TheStreet cut MyoKardia from a “c-” rating to a “d+” rating in a research report on Friday, May 19th. Zacks Investment Research cut MyoKardia from a “hold” rating to a “sell” rating in a research report on Thursday, May 11th. BMO Capital Markets reissued an “outperform” rating and issued a $32.00 price objective on shares of MyoKardia in a research report on Wednesday, May 10th. Finally, Wedbush reissued an “outperform” rating and issued a $24.00 price objective on shares of MyoKardia in a research report on Monday, March 13th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. MyoKardia presently has a consensus rating of “Buy” and a consensus target price of $23.80.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
Want to see what other hedge funds are holding MYOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MyoKardia, Inc. (NASDAQ:MYOK).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/fiduciary-trust-co-continues-to-hold-stake-in-myokardia-inc-myok/1925838.html
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.